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5-Nitrofurans are antibiotic pro-drugs that have potential as cancer therapeutics. Here, we show that 5-
nitrofurans can be bio-activated by aldehyde dehydrogenase (ALDH) 1A1/1A3 enzymes that are highly
expressed in a subpopulation of cancer-initiating (stem) cells. We discover that the 5-nitrofuran,
nifuroxazide, is selective for bio-activation by ALDH1 isoforms over ALDH2, whereby it both oxidizes
ALDH1 and is converted to cytotoxic metabolites in a two-hit pro-drug mechanism. We show that
ALDH1  melanoma cells are sensitive to nifuroxazide, while ALDH1A3 loss-of-function mutations
confer drug resistance. In tumors, nifuroxazide targets ALDH1  melanoma subpopulations with the
subsequent loss of melanoma-initiating cell potential. BRAF and MEK inhibitor therapy increases ALDH1
expression in patient melanomas, and effectively combines with nifuroxazide in melanoma cell models. The
selective eradication of ALDH1  cells by nifuroxazide-ALDH1 activation goes beyond current strategies
based on inhibiting ALDH1 and provides a rational basis for the nifuroxazide mechanism of action in
cancer.
Keywords: melanoma, ALDH, cancer stem cells, tumor-initiating cells, pro-drugs, nifuroxazide, 5-
nitrofurans, drug targets, drug mechanism of action, BRAF inhibitor
Graphical Abstract
Introduction
5-Nitrofurans are pro-drugs (i.e., they require bio-activation for activity) and have been widely used in
human and veterinary medicine for over 40 years to treat bacterial and trypanosome infections (Clayton,
2010). Recently, 5-nitrofuran antibiotics, such as nifurtimox and nifuroxazide, have been found to have anti-
cancer activity in cancers, including neuroblastoma, melanoma, multiple myeloma, colon, and breast cancer
(Nelson et al., 2008, Saulnier Sholler et al., 2006, Saulnier Sholler et al., 2011, Yang et al., 2015, Ye et al.,
2017, Zhou et al., 2012, Zhu et al., 2016). Notably, nifurtimox reduced neuroblastoma tumor burden in a
child with Chagas disease caused by trypanosome infection (Saulnier Sholler et al., 2006), and is now in a
phase II clinical trial to treat children with relapsed or refractory neuroblastoma or medulloblastoma
(NCT00601003) (Saulnier Sholler et al., 2011). When used to treat infectious disease, the relative selectivity
of the 5-nitrofurans is mediated by bio-activation by bacterial- or parasite-specific nitroreductases (Clayton,
2010). However, the mechanism by which 5-nitrofurans confer anti-cancer activity is not well understood,
limiting efforts for 5-nitrofuran drug development, patient stratification, and the development of treatment
strategies.
We previously discovered that aldehyde dehydrogenase 2 (ALDH2) is a direct target for nifurtimox and
NFN1 (a tool compound featuring a 5-nitrofuran moiety) by a small-molecule phenotypic screen in
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zebrafish (Zhou et al., 2012). ALDH enzymes are a large family of enzymes that metabolize toxic aldehydes
(Koppaka et al., 2012, Ma and Allan, 2011). ALDH  activity marks somatic stem cells, and, in many
cancers, cells with ALDH  enzymatic activity have enhanced tumorigenic potential and mark so-called
cancer stem cell subpopulations (Marcato et al., 2011, Tomita et al., 2016). Cancer cell
heterogeneity, including cancer stem cell populations, is of clinical importance because it can make
treatment difficult, drive tumor progression, and promote drug resistance (Kreso and Dick, 2014). Genetic
and phenotypic cancer cell heterogeneity is especially important in melanoma, where a majority of patients
with metastatic melanoma succumb to the disease, and even those who initially respond to targeted or
immune treatment may eventually die due to melanoma recurrence and drug resistance (Luke et al., 2017).
Despite the prevalence of the ALDH  subpopulations in multiple cancer types, there are no clinically
available drugs that specifically target such subpopulations. Clinically active ALDH inhibitors, such as
disulfiram or daidzin, are strong inhibitors for ALDH2, the principal ALDH enzyme responsible for alcohol
metabolism, as well as other possible targets (Kona et al., 2011, Koppaka et al., 2012), whereas ALDH
activity in melanoma is mediated by ALDH1A1 and ALDH1A3 (Luo et al., 2012, Yue et al., 2015). Further,
ALDH1 inhibitors, although able to reduce enzyme activity, are not designed to eradicate ALDH1
subpopulations (Koppaka et al., 2012, Tomita et al., 2016).
We hypothesized that ALDH1 might bio-activate certain 5-nitrofuran derivatives and thereby eradicate
ALDH1  melanoma-initiating subpopulations in tumors. Here, we report that 5-nitrofurans are bio-
activated by ALDH1 and show that nifuroxazide, a clinically approved 5-nitrofuran pro-drug, is selectively
bio-activated by ALDH1 enzymes over ALDH2 enzymes. This interaction is critical to mediate
nifuroxazide anti-tumor activity. Nifuroxazide-induced loss of ALDH1  subpopulations has a direct
impact on the melanoma-initiating (cancer stem) cell potential in tumors. This is of clinical importance
because we show that BRAF inhibitors lead to an increase in ALDH1  melanoma cells in matched
patient biopsies in recurrent metastatic melanoma, and that BRAF inhibitors plus MEK inhibitors lead to an
increase in ALDH1A1 mRNA in matched patient biopsies while on treatment.
Our work argues that an important mechanism of action for nifuroxazide in cancer is through the eradication
of ALDH1  cells. These findings lead to two conceptual advances in melanoma therapy that may also be
applied more widely to cancer therapy: (1) to selectively kill ALDH1  cell subpopulations, rather than
inhibit ALDH1 enzymatic activity, and (2) that the tumor-initiating and stem cell properties of cancer
subpopulations can be drug targets, rather than targeting the molecular activity of cancer mutations.
Results
ALDH1 Is a Selective Target for Nifuroxazide
We have previously demonstrated that 5-nitrofuran pro-drugs can be substrates for, and bio-activated by,
ALDH2 enzymes, leading to DNA damage and reactive oxygen species to kill cancer cells (Zhou et al.,
2012). This prompted us to test if 5-nitrofuran might be bio-activated by ALDH1, yielding an opportunity to
specifically target ALDH1  melanoma subpopulations.
To establish the range of concentration of drug activity in cells, we first tested four clinical 5-nitrofurans
(nifuroxazide, nitrofurantoin, furazolidone, and nifurtimox), our 5-nitrofuran tool compound NFN1, and the
inactive no-nitro control compound NFN1.1 (in which a hydrogen atom replaces the nitro moiety) (
Figures 1A, S1A, and S1B). Among the clinical compounds, we found nifuroxazide to have the lowest half
High
High
High
High
High
High
High
High
High
High
High
ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309505/?report=printable[5/21/2019 3:37:15 PM]
maximal effective concentration (EC ) value in A375 melanoma cell lines and used nifuroxazide as a
clinical 5-nitrofuran in our subsequent studies.
Next, we tested the potential for nifuroxazide and NFN1 to be substrates for ALDH1 and ALDH2 enzymes
in vitro. If 5-nitrofurans are bio-activated by ALDH1, they will compete for ALDH activity toward
aldehyde substrates. In this assay, ALDH enzymes metabolize aldehydes and convert NAD+ to NADH. Test
substrates that compete for ALDH activity toward aldehydes lead to a reduction in NADH production. As
positive controls, we used the ALDH1/2 inhibitor disulfiram, or the potent ALDH2 inhibitor daidzin
(Koppaka et al., 2012). We found that both nifuroxazide and the NFN1 tool compound were effective
substrates for the ALDH1 isoform ALDH1A3 (Figure 1B), which is highly expressed in melanoma-
initiating cell lines.
Surprisingly, while the NFN1 tool compound was a substrate for both ALDH1 and ALDH2 enzymes,
nifuroxazide was not an effective substrate for ALDH2 (Figure 1B). These results were validated in a
zebrafish ALDH2 activity assay (Figure S1C) (Zhou et al., 2012). Zebrafish melanocytes express ALDH2,
and treatment with nifuroxazide (up to 30 μM) did not show any toxicity toward zebrafish melanocytes,
whereas treatment with NFN1 (10 μM) significantly reduced the number of melanocytes. To further explore
the different selectivity for ALDH2 at equimolar concentrations, we purified ALDH2 and tested its activity
with increasing concentrations of NFN1 and nifuroxazide. Dose-curve analysis revealed NFN1 is a highly
selective for ALDH2 (NFN1  = 63.9 nM), while nifuroxazide had no activity toward ALDH2 up to
10 μM (Figure S1D). Thus, the antibiotic nifuroxazide is a selective substrate for ALDH1.
Next, we used the Aldefluor assay to determine if nifuroxazide might be a substrate of, and modulate,
ALDH1 activity in melanoma cells. The Aldefluor assay is based on ALDH enzyme activity to convert the
freely diffusible fluorescent BODIPY-aminoacetaldehyde to the negatively charged BODIPY-aminoacetate
that is retained and accumulates in the cell. A375 melanoma cell lines are heterogeneous for ALDH activity,
with cells presenting low, intermediate, and high fluorescence for Aldefluor activity, which can be seen by
fluorescence microscopy (Figure 1C) and used to isolate ALDH  and ALDH  subpopulations by
fluorescence-activated cell sorting (FACS) (Figure 1D). ALDH activity heterogeneity is due, at least in part,
to increased mRNA expression of ALDH1A3 in the ALDH  subpopulation compared with the
ALDH  subpopulation (Figure 1E). Nifuroxazide and NFN1 effectively reduced Aldefluor activity (
Figure 1F), indicating that nifuroxazide inhibits ALDH enzyme activity in cells. Inhibition of Aldefluor
activity was dependent on the 5-nitro moiety because our no-nitro control compound (NFN1.1) had no
effect on ALDH activity in cells (Figure S1E).
To test if 5-nitrofuran activity toward ALDH was linked to the mechanism of melanoma cell death, we
tested if N,N-diethylaminobenzaldehyde (DEAB) could prevent 5-nitrofuran cytotoxic activity in cells.
DEAB is a potent inhibitor of ALDH1, but also has broad inhibitor activity toward other ALDH enzymes
(Koppaka et al., 2012, Luo et al., 2012, Moreb et al., 2012). We found that DEAB pre-treatment protected
the cells from the cytotoxicity of NFN1 (Figure 1G). These data indicate that 5-nitrofuran pro-drug
cytotoxicity is dependent on ALDH activity.
Nifuroxazide Bio-activation Leads to Oxidation and Inhibition of ALDH1 Enzymes
ALDH1A1 and ALDH1A3 are closely related enzymes and are the predominant ALDH1 isoforms in
primary melanoma and melanoma cell lines (Luo et al., 2012). To address the molecular mechanism of how
nifuroxazide interacts with ALDH1 enzymes, we first used molecular modeling. The ALDH1A3 structure
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has recently been solved (Moretti et al., 2016) and our analysis revealed that nifuroxazide effectively fits
into the substrate pocket of ALDH1A3, predicting direct interactions with cysteines 313 and 314 in the
active site (Figures 2A and 2B).
To address the potential of 5-nitrofurans to interact with ALDH1A1, we incubated ALDH1A1 with the 5-
nitrofurans and performed mass spectrometry of the intact protein (Figure 2C). The results showed
ALDH1A1 mass increasing by +35 atomic mass units (amu), consistent with a di-oxidation with
nifuroxazide plus NAD+ (42% oxidation of total protein) or NFN1 plus NAD+ (80% oxidation of total
protein). In comparison, incubation of ALDH2 with nifuroxazide plus NAD+ did not generate the observed
mass shift, while NFN1 plus NAD+ generated both a 31-amu shift and a possible ALDH2-NFN1 adduct
(+338 amu) (Figure 2D). The nitro moiety is essential for this process because incubation of NFN1.1 did not
generate any additional species with either enzyme (Figures 2C and 2D). Likewise, oxidation of ALDH
enzymes by 5-nitrofurans was dependent on NAD+ (Figure S2).
We then used liquid chromatography-tandem mass spectrometry to determine the site of nifuroxazide-
catalyzed modification. Quantitative analysis of the modification revealed a significant increase in the
oxidation of the catalytic cysteine in the active center of ALDH1A1 upon the addition of nifuroxazide (
Figure 2E).
Together, these results demonstrate that nifuroxazide directly and specifically interacts with the ALDH1A1
and ALDH1A3 isoforms leading to oxidation and inactivation of ALDH1 isozymes at the catalytic core.
Thus, unlike ALDH1 enzymatic inhibitors, nifuroxazide has a unique two-hit mechanism whereby bio-
activation of nifuroxazide by ALDH1 enzymes leads to cytotoxicity concomitant with ALDH1 inactivation
(Figure 2F). Nifuroxazide pro-drugs provide an opportunity to move beyond inhibiting ALDH1 enzymes in
cancer cells, to selectively eradicating ALDH1-expressing cells in melanoma.
Nifuroxazide Bio-activation Is Mediated by ALDH1A3
Primary melanoma samples express high levels of ALDH1A1 and ALDH1A3, but ALDH1A3 is the
predominant form in A375 melanoma cell lines (Luo et al., 2012). If the 5-nitrofuran-ALDH1 interaction is
relevant in vivo, we would expect that loss of ALDH1 would confer resistance to 5-nitrofuran treatment.
Small interfering RNA (siRNA) knockdown of ALDH1A3 transcripts reduced ALDH1A3 protein levels and
Aldefluor activity, and validates ALDH1A3 as the dominant ALDH1 enzyme responsible for Aldefluor
activity in melanoma A375 cells (Figures 3A and 3B). Next, we tested the sensitivity of these cells to
NFN1, and found siRNA ALDH1A3 cells to have significantly reduced sensitivity to NFN1 toxicity (
Figure 3C).
Further, we generated ALDH1A3 mutant lines using CRISPR/Cas9, and selected two single-cell clones
(ALDH1A3  and ALDH1A3 ) that are predicted to be truncated in the N terminus and showed
reduced ALDH1A3 protein expression (Figures 3D and S3A) and Aldefluor activity (Figure 3E). Notably,
ALDH1A3  and ALDH1A3  cell lines had no apparent growth phenotype in culture, and grew at the
same rate as control cells indicating that ALDH1A3 is not essential for cell growth in A375 cell culture
(Figure S3B). However, ALDH1A3  and ALDH1A3  cells had significantly reduced clonogenic
potential in soft agar, an assay that tests the ability of a single-cell clonal growth in a 3D environment
(Figure S3C) and were unable to form tumors in xenografts (Figure S3D), consistent with the concept that
ALDH  subpopulations have functional tumor-initiating characteristics in melanoma cells. Importantly,
we found that ALDH1A3  and ALDH1A3  cell lines were resistant to nifuroxazide and NFN1 in cell
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growth (2D culture) and colony cultures (3D culture) (Figures 3F–3H and S3E–S3H).
Given that loss of ALDH1A3 made cells resistant to nifuroxazide, we hypothesized that overexpression of
ALDH1 should increase cell sensitivity to nifuroxazide. We overexpressed ALDH1A3 in A375 and C089
melanoma cells by transient transfection, and found that the cells were more sensitive to nifuroxazide than
control cells (Figures 3I–3L).
Thus, our genetic analysis confirms that the cytotoxic activity of nifuroxazide in these melanoma cells is
mediated by ALDH1, and not an otherwise unknown target enriched in the ALDH  subpopulation. By
extension, and in combination with our in vitro assays in Figures 1 and 2, it is likely that nifuroxazide is bio-
activated in cancers by other ALDH1 isoforms including ALDH1A1.
Nifuroxazide Selectively Kills ALDH  Subpopulations
Having established that ALDH1 enzymes are targets for nifuroxazide in cells, we wanted to test if
nifuroxazide is selectively cytotoxic for ALDH  tumor-initiating (stem cell-like) subpopulations. First,
we FACS sorted the top 5% of cells highly expressing ALDH enzyme activity (ALDH  cells) and the
bottom 5% of cells with the lowest ALDH enzyme activity (ALDH  cells) (see Figure 1D). The
ALDH  cell population had increased sphere-forming potential, which was further increased following
serial passage (Figure S4A) and were more efficient at forming colonies in soft agar (Figure 4A).
ALDH  cells also had the potential to differentiate into ALDH  and ALDH  cells over time
while maintaining an ALDH  population, whereas ALDH  cells were unable to form ALDH
populations (Figure S4B). In addition, in vivo, ALDH  cells were more tumorigenic than the ALDH
cells (Figure S4C). Together, these data validate that the top 5% of ALDH  cell populations are enriched
for phenotypic properties associated with stemness and melanoma tumor-initiating potential.
Having separated the cells into ALDH  and ALDH  populations, and validated their cellular
phenotypes, we then tested soft agar colonies derived from each population to increasing concentrations of
nifuroxazide and NFN1 (Figures 4B and S4D). We used lower concentrations of drug treatments for the
colony assay because the single cells are grown in anchorage-independent conditions and are treated over
21 days to develop into colonies. ALDH -derived colonies were highly sensitive to nifuroxazide and
NFN1. In contrast, colonies generated from ALDH  cells, while producing fewer colonies overall, were
resistant to NFN1 and nifuroxazide treatment.
We tested if the paradigm of ALDH  activity and nifuroxazide sensitivity can be extended to melanoma
cell lines representative of different melanoma genetic subtypes. We tested Aldefluor activity and
nifuroxazide sensitivity in four additional melanoma cell lines: C089 (BRAF ), C077 (NF1 ),
MEWO (NF1 ), and C092 (triple wild-type) (Ranzani et al., 2015). Aldefluor activity varied widely
among cell lines, independently of genetic subtype (Figures 4C and S4E). We found that cell lines with
relatively high median levels of ALDH activity formed colonies and were highly sensitive to nifuroxazide (
Figures 4D and S4F). In contrast, cells with relatively low median levels of ALDH activity had very low
colony formation potential and were resistant to nifuroxazide (Figures 4D and S4F).
Thus, nifuroxazide has selective activity toward multiple cell lines with overall relatively high ALDH
activity, and this is independent of melanoma genetic subtype.
Nifuroxazide Targets ALDH1  Subpopulations in Tumors
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Ultimately, we wanted to establish if ALDH  subpopulations are selective targets for nifuroxazide
in vivo and impact tumor growth. We performed a melanoma xenograft assay with human melanoma cells
that express a tdTomato transgene (A375-L2T cells) enabling us to isolate melanoma cells following
treatment. Once the tumors were established, mice were treated with nifuroxazide or with oil vehicle.
Nifuroxazide significantly attenuated tumor growth (>10 tumors) (Figures 5A and 5B). We also tested if
nifuroxazide could be effective at lower treatment concentrations, and treated A375 melanoma xenografts
with 50 or 150 mg/kg for 13 days. Both drug treatments attenuated tumor growth, and in some mice led to
partial melanoma regression suggesting that ALDH  subpopulations may be required to support
continued tumor growth (Figure S5A). These data suggest that near-maximal drug absorption or efficacy
may already be achieved at 50 mg/kg.
Following treatment, we isolated the tumors and analyzed Aldefluor activity in A375-L2T melanoma cells.
Tumors treated with nifuroxazide had reduced numbers of ALDH  cells evaluated by Aldefluor assay,
indicating that nifuroxazide can target ALDH  subpopulations directly in the tumor (Figure 5C).
Strikingly, immunohistochemistry revealed that ALDH1  cells were absent in tumors treated with
nifuroxazide (Figures 5D and 5E), accompanied by increased levels of cleaved caspase-3, an apoptosis
marker (Figures 5F and 5G). Therefore, nifuroxazide does not just inhibit ALDH enzyme activity in cells,
but specifically eradicates ALDH1  tumor subpopulations.
To assess the phenotypic outcome of targeting ALDH1  tumor-initiating subpopulations, we tested if
melanoma cells treated with nifuroxazide could initiate new tumors in serial transplantation (Figure 5H).
We removed tumors from mice that had been treated with nifuroxazide or oil vehicle, FACS sorted 10,000
melanoma cells per tumor, and injected these into recipient mice without further treatment. Melanomas from
mice that had been treated with the oil vehicle control rapidly grew tumors while, in contrast, melanomas
from nifuroxazide-treated tumors were significantly inhibited in forming new tumors (Figure 5I). These
results were validated in tumors generated from A375 cells without the tdTomato marker, whereby, due to a
lack of fluorescence, melanoma cells were selected by excluding endothelial and immune cells
(Figure S5B). Therefore, nifuroxazide effectively inhibits tumor growth in vivo by selectively targeting
ALDH1  subpopulations directly in the tumor, while surviving ALDH1  cells lack melanoma
initiation potential, and are unable to form new tumors.
Targeted Therapy Increases ALDH  Cells and Sensitivity to Nifuroxazide
Little is known about the clinical importance of ALDH1  subpopulations in human clinical samples that
have recurred following BRAF inhibitor (BRAFi) and/or MEK inhibitor (MEKi) treatment. First, we
performed immunohistochemistry for ALDH1 isoforms on seven patient melanoma samples before BRAFi
treatment and in recurrent melanoma from the same patient. The ALDH1 antibody detects both ALDH1A1
and ALDH1A3 isoforms, and thus detects ALDH1 proteins that mark ALDH1  subpopulations in
melanoma (Luo et al., 2012). As shown in Figures 6A–6D, four of the melanomas that relapsed after
treatment showed a dramatic increase in the number of ALDH1-positive cells and an increase in ALDH1
expression compared with their matched pre-treatment samples. These observations indicate that
ALDH1  subpopulations may play an important role during melanoma relapse for some patients.
Next, we tested the potential for nifuroxazide to synergize with BRAF inhibitors. In cell culture, BRAFi
lead to an adaptive increase in the number of cells expressing stemness markers, such as ALDH  24 hr
post-treatment (Figure 6E) (Ravindran Menon et al., 2015). Building on these results, we found that
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treatment with BRAFi dramatically increased the sensitivity of A375 melanoma colonies to nifuroxazide (
Figure 6F).
BRAF signaling depends on MEK activation, and the combination of BRAFi plus MEKi has improved
clinical benefit for patients with BRAF mutant melanoma (Luke et al., 2017). To establish if BRAFi plus
MEKi increases ALDH1 levels in melanoma, we analyzed RNA sequencing (RNA-seq) data of a melanoma
patient cohort before treatment and 12 ± 5 days into BRAFi plus MEKi combined treatment (European
Genome-phenome Archive: S00001000992) (Kwong et al., 2015). Of nine patients, six showed an increase
in ALDH1A1 expression while on BRAFi plus MEKi treatment (Figure 6G). These data indicate that for
some patients, BRAFi plus MEKi treatment is associated with an increase in ALDH1A1 expression.
Next, we sought to address if vemurafenib (BRAFi) plus trametinib (MEKi) treatment could lead to an
increase in ALDH activity in cell line models and provide a window of opportunity to synergize with
nifuroxazide. We found cell lines varied in response and sensitivity to the combined treatment. A375 cells
were highly sensitive to MEKi, and the addition of MEKi (2 nM) inhibited the increase in ALDH activity
promoted by the BRAFi. In contrast, low concentrations of BRAFi (50 nM) plus MEKi (0.2 nM) lead to an
increase in Aldefluor activity in A375 cells (Figure 6H). In C089 cells, BRAFi (1 μM) alone did not
significantly increase ALDH1 mRNA (Figure S6A), while the addition of MEKi alone, or BRAFi plus
MEKi, increased ALDH activity at all MEKi concentrations (0.04–2 nM) and was associated with an
increase in mRNA expression of ALDH1A1 (Figures 6H and S6A). Inhibition of the MAPK pathway with
MEKi did not increase ALDH  in D38 NRAS  mutant cells at any concentration (0.04–30 nM) (
Figure 6H). These data indicate that BRAFi plus MEKi combined therapy can lead to an adaptive increase
in ALDH  subpopulations in a subset of melanoma cell lines, although the underlying drug sensitivities
may vary. Ultimately, we tested if the therapy-induced ALDH activity increase primed the cells for
sensitivity to nifuroxazide. We found that both A375 and C089 cell lines had increased sensitivity to
nifuroxazide treatment when combined with the low doses of BRAFi plus MEKi that increase ALDH
activity (Figure 6I). These results strengthen the concept that targeted therapy leads to an adaptive increase
in ALDH1 in melanoma and provides an opportunity to treat with nifuroxazide.
Discussion
We discover that ALDH1 is a target for the widely used antibiotic nifuroxazide, and that this mechanism
selectively targets ALDH1  cells to inhibit tumor growth and initiation potential.
Our results indicate that higher levels of ALDH1 activity in melanoma are associated with increased
sensitivity to nifuroxazide, independent of melanoma genotype. This may permit cancer patient stratification
for nifuroxazide responsiveness based on ALDH1 activity. Analysis of TCGA RNA expression across
tumors reveals melanoma to be among the cancers with the highest ALDH1A3 overall expression
(Figure S6B) (Cancer Genome Atlas Network, 2015, Cerami et al., 2012, Gao et al., 2013b). Targeting
ALDH1  subpopulations may be especially important for the 50% of melanoma patients that do not have
BRAF mutations and so far have limited options for targeted therapy (Luke et al., 2017).
The clinical evidence we present here indicates that ALDH1  subpopulations increase from primary
tumor to BRAFi-resistant metastatic melanomas in some patients, suggesting that melanoma cells may
change their cellular state in response to drug treatments. This is supported by analysis of the RNA-seq
dataset from patients that reveals some patient melanomas increase ALDH1A1 expression while on BRAFi
plus MEKi. Further analysis of a published RNA microarray dataset (GEO: GSE35230) (Greger et al.,
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2012) of A375 clone 16R6-4 revealed that, despite being resistant to BRAFi plus MEKi, combined
treatment led to an increase in ALDH1A3 mRNA expression, suggesting that resistant cells are still
sensitized to therapy, and that ALDH1 expression may contribute to resistance mechanisms (Figure S6C).
This drug-induced increase in ALDH1 protein and mRNA underscores the importance in targeting
ALDH1  cells, and suggests that an important therapeutic window may be during or following targeted
therapy.
Because ALDH  subpopulations are present in many cancer types, major efforts are underway to
generate ALDH1 isoform-specific inhibitors. Given that 19 ALDH enzymes are present in the human
genome (including at least 6 within the ALDH1 family) (Koppaka et al., 2012), it is not clear at this stage if
specific ALDH1 isoform inhibitors will be sufficient to effectively target ALDH  subpopulations in
human cancers, or if other ALDH isoforms might be able to compensate and lead to drug resistance. By
contrast, we show that nifuroxazide has a two-hit mechanism, whereby it first inactivates ALDH1 through
its bio-activation, and, secondly, the bio-activated species generates cytotoxicity to kill the cell. Therefore,
rather than transiently inhibiting ALDH1  activity, nifuroxazide selectively kills ALDH1
subpopulations.
Nifuroxazide has been commonly used to treat intestinal infections such as colitis and diarrhea. Bio-
activation of 5-nitrofurans in bacteria and trypanosomes generates reactive nitro metabolites and causes
DNA damage. Repurposing nifuroxazide as an anti-cancer drug will require the identification of a
therapeutic window that selectively targets ALDH1  cells in cancer without eradicating ALDH1
stem cell populations in somatic tissues. Evidence from clinical use of nifuroxazide indicates that
nifuroxazide is generally well tolerated (Begovic et al., 2016, Bouree et al., 1989). Nifuroxazide is
administered at 800 mg/day in human patients when used as an antibiotic, while in veterinary medicine,
animals are often treated at 50 mg/kg, and higher doses (>200 mg/kg) have been described in animals
without side effects (Cagliero, 1976, Gao et al., 2013a). We find nifuroxazide is well tolerated in mice at 50
and 150 mg/kg, with no signs of side effects or weight loss. All drug administrations in our in vivo studies
are oral, as administered for patients when used as an antibiotic. This is a similar dose range used for
nifurtimox, which is used at 800 mg/day for trypanosome infection (albeit for 30–90 days), 150 mg/kg/day
for pre-clinical neuroblastoma xenograft studies for 28 days (Saulnier Sholler et al., 2009), and at
30 mg/kg/day for cancer treatment (NCT00601003) (Saulnier Sholler et al., 2011). While we cannot directly
compare the pharmacokinetics of nifurtimox with nifuroxazide, our studies suggest that nifuroxazide may be
effective at targeting ALDH1  cells in a clinically relevant dose range. Importantly, if the combined
BRAFi (plus MEKi) and nifuroxazide drug synergy we observe in cell culture holds true in the clinical
setting, this may reveal BRAFi (plus MEKi) and nifuroxazide to be a highly beneficial drug combination
and permit lower drug doses with reduced overall drug toxicity.
Despite the evidence for melanoma subpopulations in cancer progression and drug resistance, there is an
absence of drugs that specifically target phenotypic tumor-initiating cell populations available in the clinic.
Indeed, despite the use of nifurtimox in patients with neuroblastoma and medulloblastoma, the mechanism
for the anti-cancer activity is unknown. Given that ALDH1  activity marks functional stem cell
properties in neuroblastoma (Flahaut et al., 2016, Hartomo et al., 2015), ALDH1  activity might mediate
nifurtimox anti-cancer activity. Alternatively, the high levels of ALDH2 in neuroblastoma may mediate
sensitivity to nifurtimox (TARGET, 2018). Nifurtimox side effects include a disulfiram-like reaction to
alcohol, suggesting that nifurtimox activity may be preferentially bio-activated by ALDH2. This is
consistent with our observations that nifurtimox is a competitive substrate for ALDH2 (Zhou et al., 2012)
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Chemicals
and that nifuroxazide is selective for ALDH1. Understanding the mechanism of nifurtimox anti-cancer
effects may permit patient stratification protocols based on ALDH  activity in the tumor or ALDH2
patient genotypes.
In summary, we have provided substantial mechanistic insights into how a specific 5-nitrofuran used as an
antibiotic can act through ALDH1 to reduce melanoma initiation and progression. We believe that such
insights are critical to expand the pipeline of cancer drug discovery as it allows us to rationally reposition
existing drugs for therapy. The discovery that ALDH1 is a target for nifuroxazide, and that this enables the
specific killing of ALDH1  melanoma cells, goes beyond approaches of reducing the tumorigenic
potential of such cells by interfering with their ALDH1 activity, which may be limited and transient. This is
an important alternative therapeutic strategy to target phenotypically distinct tumor-initiating populations
that contribute to melanoma growth and are marked by ALDH1  activity.
Significance
One of the major challenges for cancer treatment and therapeutic design is intratumor heterogeneity,
shaped in part by phenotypically distinct tumor cell subpopulations. In melanoma, and in many other
cancers, high levels of ALDH activity (ALDH1 ) mark a subpopulation of cells with increased
tumor-initiation potential and cancer stem cell properties. Here, we show that ALDH1 is a target for
5-nitrofuran pro-drugs that are widely used to treat bacteria infections, and that have recently been
shown to have anti-cancer potential.
We have previously shown that 5-nitrofurans are bio-activated by ALDH2, the enzyme responsible
for alcohol metabolism. We now show that the 5-nitrofuran, nifuroxazide, is selective for ALDH1, and
that the cytotoxic mechanism of action in melanoma cells is mediated by eradicating ALDH1
subpopulations. This is significant because no clinically available drugs have so far emerged to
specifically eradicate ALDH1  subpopulations. We show that ALDH1  subpopulations are
enriched in patients with recurrent melanoma following BRAF inhibitor treatment and that
ALDH1A1 mRNA is increased in patient melanomas during BRAF plus MEK inhibitor treatment.
We demonstrate that nifuroxazide activity in melanoma cells is via a two-hit mechanism: bio-
activation by ALDH1 leads to toxicity in cells, coupled with oxidation and inhibition of ALDH1. Thus,
unlike ALDH inhibitors, we discover that bio-activation of 5-nitrofuran pro-drugs can selectively kill
ALDH1  cell populations. Targeting subpopulations in melanoma based on the distinctive
phenotypic properties of tumor-initiating (stem) cells, rather than targeting the molecular activity of
cancer mutations, is an orthogonal therapeutic approach to current targeted and immune therapies.
STAR Methods
Key Resources Table
Contact for Reagent and Resource Sharing
Further information and requests for reagents should be directed to the corresponding author E. Elizabeth
Patton (e.patton@igmm.ed.ac.uk).
Experimental Model Details
Vemurafenib (LKT labs), Trametinib (Selleckchem), Nifuroxazide (EMD Millipore), NFN1
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Cell Lines
In Vivo Animal Studies
Generation of ALDH1A3 Mutant Lines Using CRISPR/Cas9
(Maybridge), and clinical 5-nitrofurans were prepared as 100mM solutions in 100% dimethyl sulfoxide
(DMSO). NFN1.1 was generated in house following Zhou et al., 2012. Working solutions were freshly
prepared before addition to the cell media.
A375 cells were obtained from America Type Culture Collection (ATCC). To generate A375-
L2T cells, A375 cells were transfected with ubiquitin promoter-driven L2T (pFU-L2T) and sorted by flow
cytometry every week for 3 weeks. L2T lentivirus vector was kindly given by Dr. Sanjiv S. Gambhir
(Stanford University) to M.F. through an MTA. DMEM medium, l-glutamine, penicillin/streptomycin and
fetal bovine serum (FBS) were purchased from Life Technologies. Cells were maintained in DMEM
medium supplemented with 5μg/mL  l-glutamine, 1% penicillin/streptomycin and 10% FBS and cultured
in a humidified 5% CO  incubator at 37°C. C077, C092, C089, and MEWO cells were maintained in RPMI-
1640 medium (Life Technologies, Thermo Fisher Scientific) supplemented with 1% penicillin/streptomycin
and 10% FBS and cultured in a humidified 5% CO  incubator at 37°C. All cell lines are routinely tested for
mycoplasma by PCR every three months (date of last test June 20, 2018).
Female 6–8 week-old NOD/SCID mice were purchased from Charles River
Laboratories. Mice were used for tumor xenograft and drug treatment studies. Mice were housed in
individually ventilated cages (IVC) in groups of 5-6 mice per cage. All animal experiments were approved
by the University of Edinburgh Animal Welfare and Ethical Review Body (approval PL01-16) and the UK
Home Office (PPL 70/8897).
Method Details
We used two vector system in which the
LentiCas9-Blast vector (Addgene; 52962) contained the human codon-optimized Streptococcus pyogenes
Cas9-expression cassette and the LentiGuide-Puro (Addgene; 1000000049) contained the gRNA expression
cassette. The lentiviral vector was produced by transfection of 293T (ATCC) cells with the lentiviral vector
plasmid and packaging plasmids pCMVPAX2 (Addgene; 36052) and VSV-g (Addgene; 14888) with
polyethylenimine transfection reagent following manufacturer’s instructions. 24 hours post transfection, the
medium was replaced with fresh media and the cells were cultured for 48 hours. The lentiviral vector
containing supernatant was filtered (0.45μm filter) and A375 cells (1 × 10  cells) were transduced with 2ml
of LentiCas9-Blast virus particles in 5ml culture media and 5μg polybrene. Transduced cells were selected
with 1ng/ml blasticidin to obtain stable cell line expressing Cas9 (A375-Cas9).
SgRNA sequence was cloned in to LentiGuide-Puro. To this, oligos (100μM) were annealed and
phosphorylated in 1× T4 ligation buffer with 1× T4 PNK (New England Biolabs) and were ligated into the
BsmB1 site of the LentiGuide-Puro vector. One Shot™ Stbl3TM chemically competent E. coli were
transformed by adding 100ng of DNA and heat-shocked for 45 seconds at 42°C. Sample was spread on agar
with puromycin plates and incubated for 24 hours and single colonies were selected.
SgRNAs were expressed by a transient transfection of the A375-Cas9 cells with LentiGuide-Puro vector
described above. Briefly, 5 × 10  A375-Cas9 cells were plated in a 6 well/plate. After 24 hours A375-Cas9
cells were transfected with ALDH1A3-LentiGuide-Puro using Lipofectamine 3000 (0.3μl/well) (Invitrogen)
and P3000™ reagent (0.2μl/well). Medium was changed after 24 h. 48 h later, 0.8 μg/ml puromycin (Sigma)
was added into transfected cells. Single-cell clones were isolated for sequencing and positive clones
(ALDH1A3 , and ALDH1A3 ) were expanded in culture.
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ALDH1A3 Overexpression
siRNA Transfection
Flow Cytometry and Aldefluor Assay
Cell Viability Assay
Cytotoxicity and Apoptosis Assays Using IncuCyte ZOOM Live-Cell Imaging System
Apoptosis Detection Using Annexin V/PI
A375 cells were seeded in 96 well plat at 2.5 × 10  cells/well and incubated for
24 hours. Cells were treated 0.1μg ALDH1A3 overexpressing vector (ALDH1A3/pCMV6-XL4) (Origene)
or pCMV6-XL4 empty vector (control) in Opti-MEM™ media with Lipofectamine 3000 (0.3μl/well)
(Invitrogen) and P3000™ reagent (0.2μl/well). Medium was changed after 72 hours.
A375 cells were seeded in 96-well plate at a density of 2.5 × 10  cells/well or in 6-well
plate at a density of 5 × 10  cells/well and incubated for 24 hours. Cells were then treated with 5pmol
ALDH1A3 siRNA or scrambled control in Opti-MEM™ media with Lipofectamine RNAiMAX (1.5μl/well)
(Invitrogen). Medium was changed after 96 hours.
The aldehyde dehydrogenase (ALDH) enzyme activity was measured
using the ALDEFLUOR assay kit (STEMCell Technology) according to the manufacturer’s protocol. In
brief, cells were incubated with the fluorescent bodipy-aminoacetaldehyde (BAAA) reagent for 30 minutes
at 37°C. As a negative control, ALDH enzyme activity was blocked using diemethylamino-benzaldehyde
(DEAB). Aldefluor activity was measured using FACS Fortessa (BD Biosciences). For cell sorting, the
Aldefluor stained cells were analyzed using the FACS Aria II (BD Biosciences) and the top 5% of cell
population with highest ALDH activity (ALDH  cells), detected on the green fluorescence channel
(515–545 nm), and the bottom 5% of cells with lowest ALDH activity (ALDH  cells) were cell sorted.
Data were analyzed using FlowJo software program. Dead cells were excluded using Propidium iodide (PI,
13μM, Roche) or 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI, 3μM, Sigma-Aldrich).
Cytotoxicity of the 5-nitrofurans on melanoma cell lines was determined using the
sulforhodamine-B (SRB) cytotoxicity assay (Sigma-Aldrich). 1000 cells per well were plated in 96-well
plates overnight. Cells were then treated either with a vehicle control (DMSO) or increasing concentrations
of compounds (1nm - 100μM) for 72 hours. SRB assay was carried out as described previously (Skehan
et al., 1990). In brief, cells were fixed with Trichloroacetic acid for 1 hour at room temperature, followed by
0.4% SRB for 30 minutes at room temperature. Plates were then washed and the SRB was dissolved by
10mM Tris buffer and read at 570nm on a microplate reader. Experiments were performed in three
independent series and the mean half maximal effective concentration (EC50) was used to compare
cytotoxicity.
IncuCyte ZOOM
Live-Cell Imaging system (Essen Bioscience) was used for kinetic monitoring of cytotoxicity and apoptotic
activity of Nifuroxazide or NFN1 on melanoma cells. 1000 cells/well were seeded in 96 well plate and
allowed to attach overnight. Cells were treated with increasing concentrations (1nm - 100μM) of compounds
in the presence of Draq7™ (3μM, Abcam) and IncuCyte® NucLight BacMam 3.0 (2% v/v) (Essen
Bioscience). Draq7™ stains the nuclei in dead and permeabilized cells and IncuCyte® NucLight BacMam
3.0 enables nuclear labelling of living cells. Plates were scanned and fluorescent and phase-contrast images
were acquired in real time every 3 hours from 0 to 72 hours post treatment. Normalized green and red object
count per well was quantified at each time point and time-lapse curves were generated by IncuCyte ZOOM
software. Ratios of Draq7™level in treated cells compared to vehicle were plotted in Microsoft Excel.
10  cells were seeded in 6-well plates overnight. Cells were then
treated with compounds or vehicle for 48 hours. For detection of apoptotic cells, cells were dissociated with
cell dissociation buffer and 500μl of binding buffer was added to each sample followed by 5μg/ml of
Annexin V–FITC and 5μg/ml of PI. Samples were gently vortexed and incubated for 15 minutes at room
temperature in the dark. Samples were analysed using FACS Fortessa (BD Biosciences).
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Colony Formation Assay in Soft Agar
Sphere Formation Assay and Differentiation Assay
Western Blot Analysis
In Vivo Studies
Immunohistochemistry
5000 cells were suspended in serum free DMEM media
supplemented with 10ng/ml EGF, 10ng/ml FGF, B27 supplement (1x, Thermo Fisher Scientific), 5μg/mL
l-glutamine, and 0.3% low melting agarose (Sigma-Aldrich) in the presence or absence of compounds. Cells
were then layered over a solid base of 0.5% low melting agarose in 35mm plastic dishes. The cultures were
incubated at 37°C for 12 days. Colonies (>6 cells) from 10 separate fields were counted using a microscope
with a 4X objective.
1000 sorted ALDH  and ALDH  cells were
cultured in serum free DMEM media supplemented with 10ng/ml EGF, 10ng/ml FGF, B27 supplement
(1x), 5μg/mL  l-glutamine and then plated in low adhesion round bottom plates (Corning®). Cell
proliferation was measured by counting disaggregated single cells using a haemocytometer. Dead cells were
excluded by using 0.4% Trypan blue solution (Sigma-Aldrich).
For differentiation assay, cell sorted ALDH  and ALDH  cells were cultured in serum containing
(10% FBS) DMEM media supplemented with 5μg/mL  l-glutamine, 1% penicillin/streptomycin and
cultured in tissue culture plates for 5 days. Differentiation of cells evaluated by Aldefluor assay.
Cells were plated at 100,000 cells/well in 6-well plates and allowed to adhere
overnight. Cells were lysed with RIPA lysis buffer (Sigma-Aldrich), supplemented with a complete protease
inhibitor (Thermo Fisher Scientific Inc.). Protein concentrations were determined using the Bradford assay
(Bio-Rad Laboratories) and 25μg protein per lane was electrophoresed on a 12% SDS-polyacrylamide gel in
running buffer (Bio-Rad). Gels were transferred onto nitrocellulose membranes using the semi-dry Turbo
Transfer system with Turbo Transfer buffer (Bio-Rad). Membranes were probed using rabbit poly clonal
ALDH1A3 (1:1000, Invitrogen), and GAPDH (1:5000, Abcam) followed by goat anti-rabbit IRDye 680- or
800- labelled secondary antibodies (LI-COR Biosciences). Membranes were imaged using an Odyssey
infrared scanner (LI-COR Biosciences).
The tumorigenicity of ALDH  vs ALDH  cells was compared by injecting 50 A375
sorted cells suspended in 100μl of HBSS containing 30% matrigel (Corning). Cells were introduced via
subcutaneous injection to the right flank of mice. Tumor size was measured twice a week with a calliper.
To evaluate the cytotoxicity of nifuroxazide in vivo, NOD/SCID mice were injected with 10,000 A375-L2T
cells in 30% matrigel via subcutaneous injections. Once tumors were established, animals were allocated to
experimental group randomly so that the average tumor size within the experimental group would be the
same. Mice were treated with vehicle or 150mg/kg or 50mg/kg nifuroxazide suspended in sunflower oil via
oral gavage each day. For serial transplantation studies, once drug treatment was completed, tumors were
removed and digested into single cells. For tumor digestion, tumors were minced with a surgical blade and
single cell suspensions were generated by enzymatic digestion with 2mg/ml Collagenase D (Roche) for 1
hour at 37°C with intermittent vortexing, followed by passage through 40μm filters (Fisher Scientific). Red
blood cells were lysed using Ammonium chloride solution (STEMCELL technology). Cells were washed
twice and A375-L2T cells were cell sorted using FACS Aria. 10,000 sorted A375-L2T cells excised from
vehicle treated (DMSO) tumor or nifuroxazide treated tumor was suspended in HBSS containing 30%
standard matrigel and injected subcutaneously into 6-8 weeks old NOD/SCOD mice. Tumor growth was
measured twice a week using calliper.
Paraffin-embedded tissue samples were first de-paraffinized in xylene and re-
hydrated in graded washes of ethanol and water. Samples were boiled in pre-warmed 10mM sodium citrate
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ALDH1A3 and ALDH2 In Vitro Activity Assay
ALDH2 Protein Purification and Activity
In Silico Modeling ALDH1A3 with Nifuroxazide
(pH 6.0) for 10 minutes, followed by incubation in 3% H O  for 20 minutes and blocked in DAKO®
Protein Block Serum-Free (DAKO Agilent pathology solutions) for 1 hour at room temperature. Samples
were incubated with ALDH1A3 (1:10000, invitrogen) overnight at 4°C, followed by HRP-conjugated
secondary antibodies (Jackson ImmunoResearch Laboratories). Slides were counterstained with Mayer’s
hematoxylin for 5 minutes.
Patient samples were strained using Leia Bond-III™instrument using the IHC J protocol with Bond Polymer
Refine Red Detection System (Leica Microsystems). Antigen retrieval was performed using ER1 solution
(Leica Microsystems) for 20 minutes. Sections were then incubated with ALDH1 at 1:300 (BD Biosciences)
for 15 minutes, followed by 20 minutes post-primary AP and 30 minutes incubation with polymer AP.
Sections were then incubated with Bond Polymer Refine Red Detection System for 15 minutes and
counterstained with hematoxylin for 5 min. Slides were washed three times between each step with either
bond wash buffer or water.
The ALDH1A3 in vitro activity assay was conducted using
commercially bought ALDH1A3 (Life Technologies), and purified ALDH2-His was synthesized in-house
was used for ALDH2 (see below). ALDH (5ug) was pre-incubated at 25°C in 50mM sodium phosphate
buffer (pH7.4), 0.4mM NAD  and drug (1μM NFN1, NFN1.1; 10μM nifuroxazide) or vehicle (1% DMSO)
for 10 minutes. Disulfiram or Daidzin (10μM; ALDH1A3 & ALDH2 respectively) was used as a negative
control. The assay was initiated by the addition of 0.4mM acetaldehyde. NADH turnover was measured
using NanoDrop™ 2000 UV-Vis spectrophotometer at 340nm (ɛ = 6.22mM/cm) after 10mins to determine
ALDH activity against DMSO. Normalized ANOVA were used for statistics.
Expression from pTrcHis-TOPO® His-tagged human ALDH2
plasmid was achieved through transformation of the plasmid into BL21* E. coli and transduction with 1mM
Isopropyl β-D-1-thiogalactopyranoside (IPTG). Proteins were extracted through Constant ONESHOT Cell
Disruption lysis and lysates, then centrifuged. ALDH2-His was purified on ÄKTApurifier™ UPC 100, first
through the HiTrap IMAC FF 1mL column and then through size exclusion using HiLoad™ 16/600
Superdex™ 200 pg size exclusion. ALDH expression was confirmed by gel chromatography and purified
ALDH fractions pooled together.
Purified His-tagged ALDH2 (5μg) was pre-incubated at 25°C in 50mM sodium phosphate buffer (pH7.4),
2.5mM NAD  plus logarithmic dilution of 5-nitrofuran (NFN1 or NAZ) or 1% DMSO for 10mins. The
assay was initiated by the addition of 2.5mM acetaldehyde. NADH turnover was measured using
Spectramax M5 plate reader at 340nm (ɛ = 6.22 mM  cm ) for a total of 30mins to determine ALDH
activity. The enzymatic rate (V) and IC  values determined were determined using the initial linear change
of absorbance between 60 – 300secs. Daidzin (10μM) was used as a positive control and NFN1.1 (10μM) as
a negative control.
Water molecules and other hetero atoms were removed
from the structure of ALDH1A3 (PDB 5FHZ) and the program PDB2PQR 2.1.1 used to assigned position-
optimised hydrogen atoms, utilising the additional PropKa algorithm with a pH of 7.4 to predict protonation
states. The MGLTools 1.5.6 utility prepare_receptor4.py was used to assign Gasteiger charges to atoms.
Hydrogen atoms were assigned to compound structures using OpenBabel 2.4.1, utilising the -p option to
predict the protonation states of functional groups at pH 7.4. The MGLTools utility prepare_ligand4.py was
used to assign Gasteiger charges and rotatable bonds. Autodock 4.2.6 was used to automatically dock the
compounds into the retinoic acid binding pocket of the crystal structure. A grid box that encompassed the
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Mass Spectrometry Analysis
maximum dimensions of the cognate ligand plus 12 Å in each direction was used. The starting translation
and orientation of the ligand and the torsion angles of all rotatable bonds were set to random. The Autogrid
grid point spacing was set at 0.2 Å. The Autodock parameter file specified 50 Lamarckian genetic algorithm
runs, 7,625,700 energy evaluations and a population size of 300.
To analyze ALDH-5-nitrofuran interactions by mass spectrometry, complexes
for analysis were formed from 10.0μM of the ALDH isoenzyme with 100μM compound in 2% (v/v) DMSO
(final) with or without 500μM NAD+ and incubated for 1 hour at room temperature in 10mM HEPES,
pH7.5. Samples (2μL) were injected using an Agilent 1200SL HPLC with a low rate of 0.3mL/min
consisting of 70% H2O and 30% acetonitrile with 0.1% formic acid into an Agilent 6520 quadrupole-time
of flight (Q-TOF) mass spectrometer operating in TOF mode. The spectra were extracted and deconvoluted
using the software packages MassHunter (B.08.00) and Bioconfirm (B.08.00). The abundance levels of the
peaks were calculated on the individual deconvoluted spectra using the Bioconfirm (B.08.00) software
package.
To analyze the oxidation of ALDH cysteines by 5-nitrofuran, first all unmodified cysteines were alkylated
to prevent oxidation during the processing: cysteines already oxidized would not be alkylated, and instead
would cascade towards the triply oxidized cysteine sulfonic acid. Next, ALDH1A1 was digested into
peptides, and the modified and unmodified peptides were identified on an Agilent Model 6520 QTOF.
Proteins from the in vitro reaction were suspended in a digest buffer with a final concentration of 0.8 M
Urea, 10mM dithiotreitol and 100mM Tris-HCl pH 7.5. Protein solutions were then incubated for
30 minutes at 50°C. Reduced cysteine residues were alkylated by adding iodoacetamide solution to a final
concentration of 50mM and incubated 30 minutes at room temperature, in the dark. Proteins were digested
with by adding 0.1μg Trypsin and GluC 0.1μg (Promega) per sample for 16 hours at 37°C. Trypsin activity
was inhibited by acidification of samples to a concentration of 1% TFA. Digests were desalted on C18 Stage
tips and eluates were analysed by HPLC coupled to a Q-Exactive mass spectrometer as described previously
(Turriziani et al., 2014). Peptides and proteins were identified and quantified with the MaxQuant software
package (1.5.7.4), and label-free quantification was performed by MaxLFQ (Cox et al., 2014). The search
included variable modifications for oxidation (M, C, Y, W), dioxidation of (M,C,W), trioxidation (C),
carbamidomethylation (C) and carbamidomethylation+oxidation (C) as variable modifications. The false
discovery rate, determined by searching a reverse database, was set at 0.01 for both peptides and proteins.
Peptide oxidations were relatively quantified by [PeptideOX]/[Peptides].
Quantification and Statistical Analysis
Graphpad Prism software was used for statistical analyses. Statistical and quantification details of
experiments can be found in the figure legends. Data are presented as ±SEM of at least 3 independent
experiments. Significance was defined a p<0.05 between comparison groups.
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Figures and Tables
Figure 1
ALDH1 Is a Selective Target for Nifuroxazide
(A) Chemical structures of 5-nitrofuran compounds.
(B) ALDH1A3 and ALDH2 in vitro activity assay, with addition of 5-nitrofurans and ALDH inhibitors. Values represent
the percent NADH production relative to the DMSO control. Values are means ± SEM (n = 3; *p < 0.05; **p < 0.01; ***p
< 0.001, ns, not significant, Student's t test with Dunnett’s post-test). Nifuroxazide (NAZ) (10 μM), NFN1 (1 μM),
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disulfiram (10 μM), and daidzin (10 μM). Schematic diagram indicates mechanism of NAD+ reduction to NADH by
ALDH activity.
(C) Heterogeneity for Aldefluor activity in A375 cells. ALDH , ALDH , and ALDH  are indicated
(arrows).
(D) Flow cytometry histogram demonstrating Aldefluor activity in A375 unsorted cells and sorted ALDH  and
ALDH  cells.
(E) qRT-PCR for ALDH1A3 RNA expression in FACS sorted ALDH  and ALDH  subpopulations. Values are
normalized to GAPDH RNA expression. Values are means ± SEM (n = 3; Student’s t test).
(F) Aldefluor activity in A375 cells treated with 1 μM NFN1, 10 μM nifuroxazide, or DMSO control for 24 hr (n > 3).
DEAB used as negative control.
(G) Sensitivity of A375 cells to NFN1 +/− DEAB. Cytotoxicity was evaluated by Draq7 expression using IncuCyte Zoom.
Values are means ± SEM (n = 3; *p < 0.05; **p < 0.01, ANOVA with Tukey's test).
See also Figure S1.
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Nifuroxazide Bio-activation Leads to Oxidation and Inhibition of ALDH1 Enzymes
(A and B) Molecular modeling of ALDH1A3 with nifuroxazide (NAZ) and NAD. Nifuroxazide (color filled) forms
molecular bonds with the cysteines 313,314 in the active site.
(C and D) Mass spectrometry traces of ALDH1A1 and NAD (C), and ALDH2 and NAD (D) in combination with 5-
nitrofurans and control compounds or DMSO. Red arrows indicate oxidized ALDH1A1 and ALDH2 species, black arrows
indicate enzyme-5-nitrofuran adducts.
(E) Liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantitative analysis of oxidation of the catalytic
cysteines in the active center of ALDH1A1 with nifuroxazide. Values are normalized by dividing the intensity of the
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oxidized peptide over the sum of all intensities of all peptides identified in the protein (ratio ox-pep/protein) (*p < 0.05,
Student's t test).
(F) Schematic diagram of nifuroxazide two-hit mechanism of action. ALDH1 enzymes bio-activate the nifuroxazide pro-
drug, leading to reactive nitro species (*Nifuroxazide) and cell toxicity, and concomitantly oxidize and inactivate ALDH1.
See also Figure S2.
Figure 3
ALDH1A3 Mediates Nifuroxazide Activity
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(A) Western blot of ALDH1A3 in ALDH1A3 siRNA transfected A375 (si1A3) cells, siRNA control (siCon), and wild-type
(WT) control cells. GAPDH, loading control.
(B) Aldefluor activity in si1A3 cells or siCon cells. DEAB was used as a negative control (n > 3).
(C) Sensitivity of si1A3 and siCon cells to NFN1 measured by levels of Draq7 expression using IncuCyte Zoom. Values are
means ± SEM (n = 3, ****p < 0.0001, ANOVA with Tukey's test).
(D) Western blot of ALDH1A3 protein in ALDH1A3 knockout single-cell clones. GAPDH, loading control (n > 3).
(E) Aldefluor activity in ALDH1A3 knockout clones and A375-Cas9 WT cells. DEAB is used as negative control.
(F) Sensitivity of ALDH1A3  and A375-Cas9 cells to 10 μM nifuroxazide measured by levels of Draq7 expression using
IncuCyte Zoom. Values are means ± SEM (n = 4, ***p < 0.001, ANOVA).
(G) Representative images of WT and ALDH1A3  cells treated with nifuroxazide or DMSO, imaged with IncuCyte
Zoom. Note cell death in upper panel.
(H) Clonogenic potential of ALDH1A3 , ALDH1A3 , and control A375-Cas9 cells in soft agar. Values are means ±
SEM (n = 3, ***p < 0.001, ****p < 0.0001, ANOVA with Dunnett's test).
(I) Western blot image of ALDH1A3 protein levels in A375 cells overexpressing ALDH1A3 (transient transfection
ALDH1A3 [ttALDH1A3]) and WT control cells. GAPDH, loading control.
(J) Aldefluor activity in ttALDH1A3 and WT control. DEAB was used as negative control.
(K and L) Sensitivity of A375 (K) and C089 (L) cells, control and overexpressing ALDH1A3 to nifuroxazide. Viability was
measured using SRB assay. Values are means ± SEM (n = 3).
See also Figure S3.
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Open in a separate window
ALDH  Melanoma Cells Are Selectively Sensitive to Nifuroxazide
(A) Clonogenic potential of ALDH  and ALDH  in soft agar. Values are means ± SEM (n = 3; ***p < 0.001.
Student's t test). Representative images of colonies formed by ALDH  and ALDH .
(B) Sensitivity of ALDH  and ALDH  colonies to nifuroxazide or DMSO (control). Values are means ± SEM (n = 3;
*p < 0.05, **p < 0.01, ns, not significant, ANOVA with Dunnett's test).
(C) Geometric mean of Aldefluor activity in melanoma cells of different genetic subtypes.
(D) Sensitivity of melanoma lines to nifuroxazide as measured by number of colonies in soft agar. Values are means ± SEM
(n = 3).
See also Figure S4.
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Nifuroxazide Targets ALDH1A3  Subpopulations in Melanoma Tumors
(A) Sensitivity of A375-L2T tumors to nifuroxazide in vivo. Mice were treated with 150 mg/kg nifuroxazide or vehicle for
9 continuous days. Values are means ± SEM (n = 3 mice/condition; experimental replicates >3, *p < 0.05, two-way
ANOVA with Sidak's test).
(B) Tumor weights of control or nifuroxazide-treated mice at the end of drug treatment. Values are means ± SEM (n = 3
High
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mice/condition; experimental replicates >3, **p < 0.01; Student's t test). Image of tumors from control or nifuroxazide-
treated mice at the end of drug treatment duration.
(C) Aldefluor activity in A375-L2T cells in tumors treated with nifuroxazide or vehicle for 9 days. Note the significant shift
to the left in the tumors from nifuroxazide-treated mice indicating reduced Aldefluor activity (geometric mean of Aldefluor
activity; n = 3 p < 0.05; Student's t test).
(D) Immunohistochemistry staining of ALDH1A3 expression in melanoma tumors generated from A375-L2T cells treated
with nifuroxazide or vehicle for 5 days (n = 3). 20×. Scale bar, 100 μm. Arrows point to ALDH1  cell clusters. Mel,
melanoma tumor. Dotted lines outline tumor.
(E) Quantification of ALDH1A3-positive cells in melanoma tumors treated with nifuroxazide or vehicle. The percentage
mean of ALDH1A3-positive cells in melanoma tumors treated with nifuroxazide or vehicle from 10 random fields of view
with 10× magnification is presented (*p < 0.05; Student's t test).
(F and G) Representative image of immunohistochemistry staining, 40×. Scale bar, 50 μm (F) and quantification of cleaved
caspase-3-positive cells of melanoma cells in tumors treated with nifuroxazide or vehicle (n = 3) (G). The percentage mean
of cleaved caspase-3-positive cells from 10 random fields of view with 10× magnification is presented (**p < 0.01;
Student's t test).
(H) Schematic diagram of the experimental outline in (F) for nifuroxazide effect on tumor-initiating potential.
(I) Tumor-initiating potential of nifuroxazide- or control-treated tumors in recipient mice. Mice with established tumors
were treated with nifuroxazide or oil for 6 days, tumors were removed and isolated A375-L2T cells were injected into
recipient mice without further treatment. Values are means ± SEM (n = 3 mice/condition).
See also Figure S5.
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ALDH  Cells Are Enriched in Melanoma Patient Samples Following Targeted Therapy
(A–D) Immunohistochemistry of ALDH1 expression in melanoma patient samples. Matched patient samples were taken
before and after vemurafenib treatment. Images are shown at 2.5× and 40× magnification. Boxes indicate the region in
which the image has been captured with a 40× magnification. Scale bars, 1 mm (2.5×) and 50 μm (40×). The four of seven
matched patient samples that showed an increase in ALDH1 post-treatment are presented.
(E) Representative flow cytometry histograms of Aldefluor activity in A375 cells treated with vemurafenib (BRAFi) or
DMSO control (n = 2).
(F) Sensitivity of A375 colonies in soft agar to nifuroxazide in combination with BRAFi. Values are means ± SEM (n = 2,
*p < 0.05, ANOVA with Dunnett's test).
(G) Pair-matched FPKM fold change of melanoma ALDH1A1 and ALDH1A3 in BRAF and MEK inhibitor-treated patient
samples on-treatment versus pre-treatment, based on the RNA-seq data retrieved from the European Genome-phenome
Archive S00001000992 database. Collective fold-change values are present as means ± SEM. FPKM, fragments per
kilobase of transcript per million mapped reads.
(H) Aldefluor activity of melanoma cell lines treated with BRAFi plus trametinib (MEKi), or DMSO control 24 hr post-
treatment (n = 3). A375 (50 nM BRAFi + 0.2 nM MEKi), C089 (1 μM BRAFi + 0.04 nM MEKi), or D38 (0.04 nM MEKi).
(I) Representative flow cytometry analysis demonstrating percentage of Annexin V-positive cells. A375 cells treated with
10 μM nifuroxazide, 50 nM BRAFi, and 0.2 nM MEKi for 48 hr (n = 2). C089 treated with 5 μM nifuroxazide, 1 μM
BRAFi, or 0.04 nM MEKi for 48 hr (n = 2).
See also Figure S6.
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit poly-clonal ALDH1A3 antibody Invitrogen Cat#PA5-15000;
RRID:AB_2224038
Mouse mono-clonal GAPDH antibody Abcam Cat#Ab8245; RRID:AB_2107448
Mouse ALDH1 BD biosciences Cat#611194; RRID:AB_2224312
Cleaved Caspase-3 (Asp175) (5A1E)
Rabbit mAb
Cell Signaling Cat# 9664; RRID:AB_2070042
Goat anti mouse IRDye® 680 secondary
antibody
LI-COR Biosciences Cat#925-68070;
RRID:AB_2651128
Goat anti rabbit IRDye® 800 secondary
antibody
LI-COR Biosciences Cat#925-32211;
RRID:AB_2651127
CD271-PE Miltenyi Biotec Cat# 130-112-790
FITC anti-mouse CD45 Antibody BioLegend Cat# 103107; RRID:AB_312972)
PE anti-mouse H-2K  Antibody BioLegend Cat#116507; RRID:AB_313734
APC anti-mouse CD31 Antibody BioLegend Cat# 102409; RRID:AB_312904
Bacterial and Virus Strains
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One Shot® Stbl3™ Chemically
Competent E. coli
Invitrogen Cat#C737303
Biological Samples
Human melanoma tissue Patient samples were collected
by Melanoma Program at the
University of Pennsylvania under
Institutional Review Board (IRB)
approval Protocol #703001 and
Abramson Cancer Center’s
Protocol # UPCC 08607.
Chemicals, Peptides, and Recombinant Proteins
Acetic acid Sigma-Aldrich Cat#71251
NFN1 Maybridge Cat#BTB05727SC
Nifuroxazide EMD Millipore Cat#481984
Daidzin Sigma-Aldrich Cat#30408
Disulfiram BioVision Cat#2308
Nitrofurantoin Sigma-Aldrich Cat#67-20-9
Nifurtimox Sigma-Aldrich Cat#N3415
Furazolidone Sigma-Aldrich Cat#F9505
Vemurafenib LKT-Labs Cat#029872-54-5
DEAB STEMCELL technology Cat#01705
Propidium iodide Roche Cat#11348639001
DAPI Sigma-Aldrich Cat#D9542
RIPA Lysis buffer (10x) Sigma-Aldrich Cat#20-188
Collagenase D Roche Cat#11088858001
Ammonium Chloride Solution STEMCELL Technology Cat#07850
Annexin V, Alexa Fluor™ 555 conjugate Thermo Fisher Scientific Cat#A35108
HEPES Sigma-Aldrich Cat#7365-45-9
Cell Dissociation Solution Non-
enzymatic
Sigma-Aldrich Cat#C5914
Complete Protease inhibitor Thermo Fisher Scientific Cat#A32953
T4 DNA Ligase New England Biolabs Cat#M0202M
T4 DNA Ligase Reaction Buffer New England Biolabs Cat#B0202S
Human Recombinant ALDH1A1 Life Technologies Cat#11388H07E25
Human Recombinant ALDH1A3 Life Technologies Cat#11636H07E5
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Human Recombinant ALDH2 BioVision Cat#6332
Matrigel Growth Factor Reduced Corning Cat#356230
EGF Thermo Fisher Scientific Cat#PHG0313
FGF-Basic R&D Cat#233-FB-025/CF
B27 Supplement Thermo Fisher Scientific Cat#17504044
Low Melting Agarose Sigma-Aldrich Cat#A4018
Trametinib Selleckchem Cat#S2673
Critical Commercial Assays
Aldefluor Assay STEMCELL technology Cat#01705
Cell Meter™ APC-Annexin V Binding
Apoptosis Assay Kit
AAT Bioquest® Cat# 22837
Draq7™ Abcam Cat#Ab109202
IncuCyte® NucLight BacMam 3.0 Essen Bioscience Cat#4622
Bond Polymer Refine Red Detection
System
Leica Biosystems Cat#DS9390
Dako REALTM EnVisionTM Detection
System, Peroxidase/DAB+,
Rabbit/Mouse
DAKO Cat#K5007
DAKO® Protein block serum-free DAKO Cat#X0909
Sulforhodamine B sodium salt (SRB) Sigma-Aldrich Cat#S1402
Bradford Assay Bio-Rad Cat#500-0006
Lipofectamine® RNAiMAX
Transfection Reagent
Invitrogen Cat#13778150
Lipofectamine® 3000 Transfection
Reagent
Invitrogen Cat#L3000008
Polyethylenimine, Linear, MW 25000,
Transfection Grade
Polysciences Cat#23966-1
Experimental Models: Cell Lines
A375 ATCC Cat#CRL-1619;
RRID:CVCL_0132
293T ATCC Cat#CRL-3216;
RRID:CVCL_0063
C077 ABN Cell Line Bank, QIMR
Berghofer Medical Research
Institute
C089 ABN Cell Line Bank, QIMR
Berghofer Medical Research
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Institute
C092 ABN Cell Line Bank, QIMR
Berghofer Medical Research
Institute
MEWO ABN Cell Line Bank, QIMR
Berghofer Medical Research
Institute
D38 ATCC
Experimental Models: Organisms/Strains
Mouse: NOD SCID Charles River RRID:IMSR_ARC:NODSCID
Oligonucleotides
siRNA sequence; Silencer® Select;
ALDH1A3,
GUAUCGAAGAAGUGAUAAA
Life technology Cat#4390824
gRNA sequence, ALDH1A3;
CACCGCTACATGTAACCCTTCAACT
This paper N/A
Recombinant DNA
ALDH1A3 human cDNA clone pCMV6-
XL4 vector
Origene Cat#SC119706
pCMV6-XL4 vector Origene Cat#PCMV6XL4
lentiCas9-Blast vector (Sanjana et al., 2014) Addgene; 52962
lentiGuide-Puro vector (Sanjana et al., 2014) Addgene; 1000000049
pCMVPAX2 (Lang et al., 2000) Addgene; 36052
VSV.G (Reya et al., 2003) Addgene; 14888
Software and Algorithms
MaxQuant version 1.5.7.4 http://www.coxdocs.orgi
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